---
document_datetime: 2023-09-21 19:17:29
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/steps-after-cutoff/optison-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
document_name: optison-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf
version: success
processing_time: 1.2232737
conversion_datetime: 2025-12-25 08:26:37.397944
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## STEPS TAKEN AFTER GRANTING THE MARKETING AUTHORISATION

## For procedures finalised after 1 September 2004 please refer to module 8B.

- On  10  September  1998  the  marketing  authorisation  holder  submitted  a  request  pursuant  to Article 10(3) of Council Directive 92/27/EEC in order to change the package leaflet with regard to the address of the local representative for Optison in the Netherlands. A Notification (N01) was duly prepared, and the revised Decision was issued by the Commission on 19 November 1998.
- On 5 October 1998 the Marketing Authorisation Holder submitted to the EMEA an application for a Type I variation in accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The scope of this variation was to include Mallinckrodt Medical Imaging Ireland  as  an  additional  site  for  the  labelling  and  packaging  of  Optison  bulk  material.  This variation  was  approved  by  the  EMEA  on  5  November  1998  and  did  not  require  any amendments to the Commission Decision
- On  5  October  1998  the  Marketing  Authorisation  Holder  submitted  to  the  EMEA  two applications for Type I variations in accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended, arising from the marketing authorisation holder's Follow Up Measure commitments. I/03 was a request to add a limit test for albumin aggregates into the product specification rejected on grounds of insufficient supporting data). I/04 related to a test with  limits  for  content  of  octafluoropropane  in  the  product.  Following  an  extension  of  the procedure for additional data, this variation was approved on 18 December 1998 and did not require any amendments to the Commission Decision
- An  application  to  amend  the  contact  addresses  in  the  package  leaflet  was  approved  by Notification under Article 10(3) of Council Directive 92/27/EEC, on 18 May 1999. A revised Commission Decision was issued 29 June 1999.
- On 31 March 1999 the Marketing Authorisation Holder submitted to the EMEA an application for a Type I variation in accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995,  as  amended.  The  scope  of  this  variation  was  a  change  in  in-process  controls  applied during the manufacture of the product. This variation was approved by the EMEA on 4 May 1999 and did not require any amendments to the Commission Decision.
- On 21 April 1999 the Marketing Authorisation Holder submitted to the EMEA an application for a Type I variation in accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The scope of this variation was to register FluoroMed, L.P. as an additional alternative  supplier  of  an  intermediate  compound  used  in  the  manufacture  of  the  active substance. The CPMP at the May 1999 plenary meeting adopted a request for the new site to be inspected. The procedure was therefore extended. This variation was approved by the EMEA on 19 August 1999 and did not require any amendments to the Commission Decision.
- An  application  to  amend  the  contact  addresses  in  the  package  leaflet  was  approved  by Notification under Article 10(3) of Council Directive 92/27/EEC, on 27 January 2000.
- On 7 April 2000 the Marketing Authorisation Holder submitted to the EMEA two applications for  Type I variations in accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The scope of these variations was a change in the specifications of excipients in the medicinal product and a minor change in the manufacture of the medicinal product. This variations were approved by the EMEA on 8 May 2000 and did not require any amendments to the Commission Decision.
- On 18 April 2000 the Marketing Authorisation Holder submitted to the EMEA an application for  a  Type  II  variation  in  accordance  with  Commission  Regulation  (EC)  No.  542/95  of  10 March 1995, as amended. The scope of this variation was to update the SPC and the Package Leaflet  following  the  assessment  of  the  2 nd and  3 rd PSUR,  to  include  under  section  4.8  rare adverse events of allergic type and transient nervous and visual disorders. The CPMP adopted a positive opinion for this variation on 27 July 2000. A revised Commission Decision was issued on 29 November 2000.

<div style=\"page-break-after: always\"></div>

- On 25 April 2000 the Marketing Authorisation Holder submitted to the EMEA an application for a Type I variation in accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The scope of this variation was a minor change in the manufacturing process of the active substance. This variation was approved by the EMEA on 26 May 2000 and did not require any amendments to the Commission Decision.
- On 28 April 2000 the Marketing Authorisation Holder submitted to the EMEA an application for a Type I variation in accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The scope of this variation was a change in the specification of the medicinal product. This variation was a consequence to a follow up measure regarding limit for percent polymers and aggregates accepted at the CPMP meeting held in January 2000. This variation was  approved  by  the  EMEA  on  31  May  2000  and  did  not  require  any  amendments  to  the Commission Decision.
- On 17 July 2000 the Marketing Authorisation Holder submitted to the EMEA an application for a  Type I variation in accordance with Commission Regulation (EC) No. 542/95 of 10 March 1995, as amended. The scope of this variation was a change in the name of the manufacturing site  of  the  finished  product Optison  Molecular  Byosistems Inc  to Mallinckrodt  Inc .  This variation was approved by the EMEA on 9 August 2000 and did not require any amendments to the Commission Decision.

Subsequent post Marketing Authorisation applications agreed upon are summarised in the table below:

| Scope                                                                                                                                                                                                                       | Application number   | Type of modification 1   | Notification/ Opinion issued on 2   | Commission Decision Issued/amended on   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|--------------------------|-------------------------------------|-----------------------------------------|
| Change in the name of the medicinal product (either invented name of common name): the MAHapplied to change the name of the INN from octafluoropropane to perflutren, following a recommendation from the WHOINN Committee. | I/0016               | I                        | 14.05.01                            | --                                      |
| Minor change in labelling or package leaflet not connected with the SPC (Art. 10.3 Notification)                                                                                                                            | N/0017               | N                        | 05.06.01                            | 08.10.01                                |
| Change in the contact details of the local representatives on the package leaflet in all official languages.                                                                                                                | N/0018               | N                        | 13.03.02                            | 18.04.02                                |
| Transfer of MAH                                                                                                                                                                                                             | T/0019               | T                        | 26.03.02                            | 29.04.02                                |
| Bulk finished product manufacturing change                                                                                                                                                                                  | II/0020              | II                       | 19.09.02                            | 20.11.02                                |
| Transfer of the manufacturing site for outer packaging and batch release                                                                                                                                                    | I/0021               | I                        | 15.01.03                            | 17.03.03                                |
| Renewal                                                                                                                                                                                                                     | R/0022               | R                        | 20.02.03                            | 15.05.03                                |
| Addition of new plasma sources                                                                                                                                                                                              | II/0023              | II                       | 25.09.03                            | 26.09.03                                |
| Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                            | II/0024              | II                       | 23.06.04                            | 12.08.04                                |